Mealey's (July 22, 2016, 12:13 PM EDT) -- LOS ANGELES — A drug maker will pay $95 million to settle claims that it misrepresented certain safety concerns with two of its products in violation of federal securities laws, according to a motion for preliminary approval of settlement filed July 21 in California federal court (In re Amgen Inc. Securities Litigation, No. 07-2536, C.D. Calif.).

(Motion for preliminary approval of settlement available. Document #57-160815-003B. Stipulation of settlement available. Document #57-160815-004B.)

Under the terms of the settlement, which are subject to court approval, Amgen Inc. will...